A detailed history of China Universal Asset Management Co., Ltd. transactions in Centessa Pharmaceuticals PLC stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 13,593 shares of CNTA stock, worth $233,255. This represents 0.02% of its overall portfolio holdings.

Number of Shares
13,593
Previous 6,808 99.66%
Holding current value
$233,255
Previous $61,000 255.74%
% of portfolio
0.02%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$8.58 - $16.99 $58,215 - $115,277
6,785 Added 99.66%
13,593 $217,000
Q2 2024

Jul 19, 2024

SELL
$8.04 - $11.87 $32,232 - $47,586
-4,009 Reduced 37.06%
6,808 $61,000
Q1 2024

Apr 29, 2024

BUY
$6.73 - $12.2 $29,766 - $53,960
4,423 Added 69.17%
10,817 $122,000
Q4 2023

May 21, 2024

SELL
$5.52 - $8.03 $24,414 - $35,516
-4,423 Reduced 40.89%
6,394 $50,000
Q4 2023

Jan 23, 2024

BUY
$5.52 - $8.03 $27,804 - $40,447
5,037 Added 371.19%
6,394 $51,000
Q3 2023

May 21, 2024

BUY
$6.01 - $8.24 $4,002 - $5,487
666 Added 96.38%
1,357 $8,000
Q3 2023

Oct 30, 2023

BUY
$6.01 - $8.24 $4,002 - $5,487
666 Added 96.38%
1,357 $9,000
Q2 2023

May 21, 2024

SELL
$3.68 - $6.9 $77 - $144
-21 Reduced 2.95%
691 $4,000
Q2 2023

Jul 27, 2023

SELL
$3.68 - $6.9 $77 - $144
-21 Reduced 2.95%
691 $4,000
Q1 2023

May 21, 2024

BUY
$3.03 - $4.0 $542 - $716
179 Added 33.58%
712 $2,000
Q1 2023

Apr 27, 2023

BUY
$3.03 - $4.0 $542 - $716
179 Added 33.58%
712 $3,000
Q4 2022

May 21, 2024

SELL
$3.05 - $4.19 $31,366 - $43,089
-10,284 Reduced 95.07%
533 $1,000
Q4 2022

Jan 31, 2023

BUY
$3.05 - $4.19 $158 - $217
52 Added 10.81%
533 $2,000
Q3 2022

Oct 21, 2022

BUY
$3.8 - $5.91 $1,827 - $2,842
481 New
481 $2,000

Others Institutions Holding CNTA

About Centessa Pharmaceuticals plc


  • Ticker CNTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,339,296
  • Market Cap $1.62B
  • Description
  • Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; an...
More about CNTA
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.